Feb 13, 2019 / 09:30PM GMT
Operator
Welcome to the DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children 4 to 11 Years of Age. My name is James. I'll be your operator for today's call. (Operator Instructions)
Also note that this conference is being recorded. And now I'd like to turn the call over to Susanna Mesa. Susanna, you may begin.
Susanna Mesa - DBV Technologies S.A. - Chief Business Officer
Thank you, James, and thank you all of you for joining today's call. Earlier today, we issued a press release providing our new update on the anticipated regulatory pathway for Viaskin Peanut, our lead product candidate for the treatment of peanut-allergic children 4 to 11 years of age. This press release is available in our website at dbv-technologies.com as well as the SEC website. Joining me on the call today are our CEO, Daniel Tassé; and our Manufacturing and Operations Leader, Julie OâNeill. Daniel and Julie will each deliver remarks, and then we'll open the call for Q&A.
Before we start, I would like to note
DBV Technologies SA To Provide Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children Corporate Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot